ATE292144T1 - Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren - Google Patents

Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren

Info

Publication number
ATE292144T1
ATE292144T1 AT02291962T AT02291962T ATE292144T1 AT E292144 T1 ATE292144 T1 AT E292144T1 AT 02291962 T AT02291962 T AT 02291962T AT 02291962 T AT02291962 T AT 02291962T AT E292144 T1 ATE292144 T1 AT E292144T1
Authority
AT
Austria
Prior art keywords
tumors
shiga toxin
cys
diagnosis
vector
Prior art date
Application number
AT02291962T
Other languages
English (en)
Inventor
Ludger Johannes
Jean-Claude Florent
David Grierson
Philippe Maillard
Sylvie Robine
Jacky Roger
Original Assignee
Inst Curie
Univ Paris Curie
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Curie, Univ Paris Curie, Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Inst Curie
Application granted granted Critical
Publication of ATE292144T1 publication Critical patent/ATE292144T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nanotechnology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02291962T 2002-08-02 2002-08-02 Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren ATE292144T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02291962A EP1386927B1 (de) 2002-08-02 2002-08-02 Shiga-Toxin-Untereinheit B als Vektor zur Diagnose von Tumoren und zur Arzneimittelverabreichung an GB3-exprimierenden Tumoren

Publications (1)

Publication Number Publication Date
ATE292144T1 true ATE292144T1 (de) 2005-04-15

Family

ID=30011281

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02291962T ATE292144T1 (de) 2002-08-02 2002-08-02 Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren
AT03775133T ATE439597T1 (de) 2002-08-02 2003-07-31 Shiga-toxin-untereinheit b als vektor für die tumordiagnose und zur arzneimttelverabreichung an gb3-exprimierenden tumoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03775133T ATE439597T1 (de) 2002-08-02 2003-07-31 Shiga-toxin-untereinheit b als vektor für die tumordiagnose und zur arzneimttelverabreichung an gb3-exprimierenden tumoren

Country Status (9)

Country Link
US (3) US7718601B2 (de)
EP (2) EP1386927B1 (de)
JP (1) JP4339251B2 (de)
AT (2) ATE292144T1 (de)
AU (1) AU2003283228A1 (de)
CA (1) CA2494541C (de)
DE (2) DE60203491D1 (de)
ES (1) ES2330429T3 (de)
WO (1) WO2004016148A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229045A1 (de) * 2001-02-01 2002-08-07 Institut Curie Universeller Träger zum Zielrichten von Molekülen zu Rezeptor Gb3 - exprimierenden Zellen
ATE292144T1 (de) * 2002-08-02 2005-04-15 Inst Curie Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren
AR047692A1 (es) * 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
KR20080050503A (ko) * 2005-10-12 2008-06-05 시바 홀딩 인코포레이티드 캡슐화된 발광 안료
US20110152252A1 (en) * 2007-12-18 2011-06-23 Institut Curie Shiga toxin b-subunit/chemotherapeutics conjugates
EP2072060A1 (de) 2007-12-18 2009-06-24 Institut Curie Verfahren und Zusammensetzungen zur Herstellung und Verwendung von Toxinkonjugaten
CN102458442B (zh) * 2009-04-08 2016-06-29 加利福尼亚大学董事会 具有受控血清药代动力学的人蛋白支架
EP2740491A1 (de) * 2012-12-05 2014-06-11 Institut Curie Konjugate der B-Untereinheit von Shiga-Toxin zur Verwendung als Kontrastmittel zur Bildgebung und Therapie
US20160347798A1 (en) 2014-01-27 2016-12-01 Molecular Templates, Inc. Mhc class i epitope delivering polypeptides and cell-targeted molecules for direct cell killing and immune stimulation via mhc class i presentation and methods regarding the same
ES2717751T3 (es) * 2014-06-11 2019-06-25 Molecular Templates Inc Polipéptidos efectores de la subunidad A de la toxina de Shiga resistentes a la escisión por proteasa y moléculas dirigidas a células que los comprenden
MX391965B (es) 2016-06-16 2025-03-21 Oncoselect Therapeutics Llc Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
CA3044303A1 (en) * 2016-11-09 2018-05-17 Griffith University Subtilase cytotoxin b subunit mutant
WO2018192719A1 (en) 2017-04-20 2018-10-25 Institut National De La Sante Et De La Recherche Medicale Peptides, especially polypeptides, phage display screening method and associated means, and their uses for research and biomedical applications

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6075432A (ja) * 1983-08-08 1985-04-27 Kuraray Co Ltd ネオカルチノスタチン誘導体及びその製造方法
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5250565A (en) * 1987-02-10 1993-10-05 Abbott Laboratories Indole-,benzofuran-,and benzothiophene-containing lipoxygenase-inhibiting compounds
US5753627A (en) * 1988-12-05 1998-05-19 Novartis Ag Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5326778A (en) * 1992-03-03 1994-07-05 Research Corporation Technologies, Inc. Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5840485A (en) * 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
AU8091694A (en) * 1993-10-26 1995-05-22 United Biomedical Inc. Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
DE4430601A1 (de) * 1994-08-22 1996-02-29 Beiersdorf Ag Zelladhäsions-Peptide zur Modifikation des Haftungsverhaltens eukaryontischer Zellen untereinander
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
US5801145A (en) * 1996-02-09 1998-09-01 Ontario Cancer Institute Method for selectively purging CD77+ cells from bone marrow
US6368598B1 (en) * 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
FR2766193B1 (fr) 1997-07-18 2001-09-14 Inst Curie Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
AU3798500A (en) * 1999-04-09 2000-11-14 Hsc Research And Development Limited Partnership Verotoxin treatment of lymphomas
JP2004501664A (ja) * 2000-06-30 2004-01-22 ボード・オブ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム 標的化薬剤送達のための腫瘍組織を浸潤する細胞特異的な内部移行ペプチドの単離
EP1229045A1 (de) * 2001-02-01 2002-08-07 Institut Curie Universeller Träger zum Zielrichten von Molekülen zu Rezeptor Gb3 - exprimierenden Zellen
EP1434778A4 (de) * 2001-05-31 2005-07-13 Medarex Inc Cytotoxine und prodrugs, linker und stabilisatoren dafür
ATE292144T1 (de) * 2002-08-02 2005-04-15 Inst Curie Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren
US20110152252A1 (en) * 2007-12-18 2011-06-23 Institut Curie Shiga toxin b-subunit/chemotherapeutics conjugates

Also Published As

Publication number Publication date
CA2494541C (en) 2011-10-18
JP4339251B2 (ja) 2009-10-07
EP1386927B1 (de) 2005-03-30
ES2330429T3 (es) 2009-12-10
US20100329992A1 (en) 2010-12-30
US20110243914A1 (en) 2011-10-06
DE60328789D1 (de) 2009-09-24
US7718601B2 (en) 2010-05-18
DE60203491D1 (de) 2005-05-04
EP1386927A1 (de) 2004-02-04
EP1525478A2 (de) 2005-04-27
US20060008475A1 (en) 2006-01-12
US8313731B2 (en) 2012-11-20
AU2003283228A1 (en) 2004-03-03
US7981400B2 (en) 2011-07-19
WO2004016148A2 (en) 2004-02-26
ATE439597T1 (de) 2009-08-15
JP2006509727A (ja) 2006-03-23
AU2003283228A8 (en) 2004-03-03
CA2494541A1 (en) 2004-02-26
WO2004016148A3 (en) 2004-10-28
EP1525478B1 (de) 2009-08-12

Similar Documents

Publication Publication Date Title
ATE292144T1 (de) Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren
Hennard et al. Synthesis and Activities of Pyoverdin− Quinolone Adducts: A Prospective Approach to a Specific Therapy Against Pseudomonas a eruginosa
US12377155B2 (en) Bicyclic peptide ligands specific for PSMA
EP2357006A3 (de) Arzneimittelkonjugate und deren Verwendung zur Behandlung von Krebs, einer Autoimmunerkrankung oder einer Infektionskrankheit
DE602004027888D1 (de) Anti-cd70 antikörper-arzneimittelkonjugate und ihr
WO2007100385A3 (en) Macrocyclic depsipeptide antibody-drug conjugates and methods
CN104244718A (zh) 抗体-药物缀合物以及相关化合物、组合物和方法
EP1988910A4 (de) Acryloyloxyethylphosphorylcholin-haltige polymerkonjugate und ihre zubereitung
WO2004019878A3 (en) Adzymes and uses thereof
CN102639561A (zh) 多价抗体
WO2020148525A1 (en) Bicyclic peptide ligands specific for caix
US20220133733A1 (en) Bicyclic peptide ligands specific for cd38
JP7780253B2 (ja) ステープルペプチドの細胞内送達のためのポリペプチド接合体
US20220064218A1 (en) Bicyclic peptide ligands specific for cd38
CN118414169A (zh) 反式环辛烯缀合物
EP4422696A1 (de) Tetrazinkonjugate zur gezielten in-vivo-abgabe einer nutzlast
Safavy et al. Site-Specifically Traced Drug Release and Biodistribution of a Paclitaxel− Antibody Conjugate toward Improvement of the Linker Structure1
Akaiwa et al. Synthesis and evaluation of linear and macrocyclic dolastatin 10 analogues containing pyrrolidine ring modifications
CN116036303A (zh) 一种抗体-药物偶联物及其制备方法和应用
JP7038663B2 (ja) 環中に少なくとも２個の（－ｃｈ２－ｃｈ２－０－）単位を含むリンカーを含むコンジュゲート及びコンジュゲート試薬
AU2002362210A1 (en) Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon
Walker et al. Monoclonal antibody mediated intracellular targeting of tallysomycin S10b
Pettit et al. Antineoplastic agents. 604. The path of quinstatin derivatives to antibody drug conjugates
Kintzing A Toolbox of Peptide-Drug Conjugates for Targeted Chemotherapy
WO2007101252A3 (en) Targeted delivery of pharmaceutical compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties